Chronic Kidney Disease Drugs Are Being Studied By Researchers around the World to Develop New and Effective Treatment

Chronic Kidney Disease Drugs
Chronic Kidney Disease Drugs

Chronic kidney disease patients often experience polypharmacy, resulting in a complex medication regimen. To understand the role of drug interactions in chronic kidney disease, it's helpful to look at the prescription patterns of patients with the disease. A study of 96 patients found 149 pDDIs in their prescription records, with 4.1% of these cases being classified as severe or moderate. The remaining 75.1% were minor and undetectable.

Currently, dapagliflozin (BI10773) is an investigational therapy for chronic kidney disease. It is one of the Chronic Kidney Disease Drugs being studied by Boehringer Ingelheim. It inhibits the sodium-glucose co-transporter-2 (SGLT2) enzyme and is non-absorbed. This medication is used to treat hyperuricemia, which causes high levels of urate in the bloodstream, which can lead to kidney stones and other diseases.

When prescribing medications, physicians should keep in mind that patients with CKD have a number of other comorbid conditions. Chronic Kidney Disease Drugs reduce the ability of these organs to properly process and eliminate many drugs. Due to this, medication doses should be adjusted accordingly. Along with the active drug, many medications contain active metabolites that accumulate in the body, resulting in an increased risk of toxicity and complications.

The primary cause of the end-stage renal disease is diabetes or hypertension. The best treatment for this disease is one that will improve kidney function and control symptoms. Depending on the severity of the disease, it may be beneficial to consider a dialysis machine or an artificial dialysis machine. This type of medical equipment will speed up the process of treatment. When it's time to start a new treatment, it's important to look at the different treatments available for chronic kidney disease.

Despite the current shortage of effective CKD drugs, there are some promising ones in the pipeline. SGLT2 inhibitors and diuretics are only a few of the many promising new Chronic Kidney Disease Drugs Market in development. In addition to SGLT2 inhibitors, Bayer's mineralocorticoid receptor antagonist Kerendia is touted as a blockbuster. The drug has already doubled in popularity from just six months ago, and its usage has tripled in just one year. Recently in August 2021, the Ministry of Health, Labour and Welfare (MHLW), Japan granted approval to Forxiga (dapagliflozin) of AstraZeneca for treating CKD in adults suffering from type-2 diabetes and adults without diabetes.

Comments

Popular posts from this blog

Biopreservation Have Become Important Tool For Bioengineering, Computer Sciences, Molecular Biology, And Cellular Biology

Cancer Biologics Is A Biological Therapy That Is Made By Reproducing, Or Growing, Cells In A Carefully Controlled Laboratory Setting

Global Battery Market Is Expanding Owing To Increasing Resource Conservation And Growing Public Awareness